Health Catalyst Appoints Simeon Kohl as CEO with 2.75M RSU Inducement Grant
Resolved · corporate · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-15. Check what remains unresolved below before relying on it.
Does this insider transaction strengthen the investment case?
Executive leadership transition and a 2.75M RSU equity inducement package alter HCAT's corporate governance profile and share dilution schedule.
| Question | What the evidence establishes |
|---|---|
| Did the insider change their personal exposure? | Reported factHealth Catalyst (HCAT) appointed Simeon Kohl as Chief Executive Officer and President, effective September 14, 2026. |
| On what terms? | Reported factKohl received an inducement grant of 2,747,385 restricted stock units under Nasdaq Listing Rule 5635(c)(4). |
| Is this unusual buying or selling activity? | UnknownPrior insider transactions for this company are not in the public record here. |
| Does it establish improving business performance? | UnknownNot by itself. A transaction reflects one person's decision; operating results are needed to test it. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for HCAT yet — this is the next research task. |
| What would change the assessment? | UnknownHCAT Strategic Roadmap Presentation — Monitor executive commentary regarding strategic priorities and commercial customer retention. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Health Catalyst (HCAT) appointed Simeon Kohl as Chief Executive Officer and President, effective September 14, 2026.
- · Kohl received an inducement grant of 2,747,385 restricted stock units under Nasdaq Listing Rule 5635(c)(4).
- · The equity award vests over approximately two years, with the initial tranche of 915,975 RSUs vesting after one year.
Public research record
Research framework · page evidenceCompleted event assessment
executive leadership transition and equity dilution
| Type | Claim | Scope |
|---|---|---|
| Assumption | Health Catalyst (HCAT) appointed Simeon Kohl as Chief Executive Officer and President, effective September 14, 2026. | 2026-09-15 |
| Interpretation | executive leadership transition and equity dilution | HCAT |
Countercase, invalidators, and sources
New leadership accelerates enterprise healthcare provider data contract wins and improves EBITDA margin conversion.
- · HCAT Strategic Roadmap Presentation — Monitor executive commentary regarding strategic priorities and commercial customer retention.
- Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) · 2026-09-14
What remains unresolved
- Base path
- HCAT executes strategic roadmap under new executive leadership while absorbing equity dilution.
- Adverse path
- Leadership turnover delays strategic enterprise sales cycles and increases executive churn.
- Supportive path
- New leadership accelerates enterprise healthcare provider data contract wins and improves EBITDA margin conversion.
- · HCAT Strategic Roadmap Presentation — Monitor executive commentary regarding strategic priorities and commercial customer retention.this week
Evidence
- Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)2026-09-14
“Health Catalyst, Inc. announced the appointment of Simeon Kohl as Chief Executive Officer and President effective September 14, 2026. As part of his employment inducement, Kohl was granted 2,747,385 restricted stock units...”
Supports: Simeon Kohl appointed CEO of HCAT with 2,747,385 RSUs granted as an inducement award.